홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Bosentan

HCID 104865
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
147536-97-8
표준 SMILES
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO
InChIKey
GJPICJJJRGTNOD-UHFFFAOYSA-N
분자식
C27H29N5O6S
평균 분자량
551.6 g/mol
단동위원소 질량
551.18385484

개요

Bosentan is a primary alcohol, a sulfonamide and a member of pyrimidines. It has a role as an antihypertensive agent and an endothelin receptor antagonist.

이름 및 식별자

우선 이름
Bosentan
IUPAC
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
영어명
Bosentan
분자식
C27H29N5O6S
분자량
551.61

이름 및 동의어

Bosentan147536-97-8Tracleerbosentan anhydrousbosentanumRo 47-0203Anhydrous bosentanRo-47-02034-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamideDTXSID7046627p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamideRo-47-0203/029
이름 더 보기
Bosentan impurityBosentan USP/EP/BPActelionro47-0203ro47-0203/039Bosentan 13C6Bosentan - Bio-X ?bosentan , CID 104865Bosentan, 10 mM in DMSO
XUL93R30K24-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamideBenzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-DTXCID5026627CHEBI:514504-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamideBenzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-Ro-470203029

데이터베이스 식별자

물성

구조 계산 물성

XLogP
3.8
극성 표면적
154 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
11
회전 가능 결합 수
11
무거운 원자 수
39
형식 전하
0
복잡도
839

실험 및 물리화학적 성질

Drugs · 3건

Pharmaceuticals

Pharmaceuticals -> Antihypertensives

Pharmaceuticals -> Listed in ZINC15

LogP · 2건

3.7

1.99

Solubility · 2건

Poorly soluble in water (1.0 mg/100 ml) and in aqueous solutions at low pH (0.1 mg/100 ml at pH 1.1 and 4.0; 0.2 mg/100 ml at pH 5.0). Solubility increases at higher pH values (43 mg/100 ml at pH 7.5).

9.04e-03 g/L

Human Drugs · 4건

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Cardiovascular Agents; Endothelin Receptor Antagonists; Vasodilator Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physical DescriptionSolid
Collision Cross Section229.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID80873178]

물리화학적 성질

녹는점
107 · 107-110°C
끓는 점
742.3 · 742.3±70.0 °C(Predicted)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P273, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (40%)

독성 정보

Hepatotoxicity · 1건

Bosentan is associated with elevations in serum aminotransferase levels above three times the upper limit of the normal range (ULN) in 3% to 18% of patients, averaging 7.6% using currently recommended doses. The enzyme elevations are usually self-limited and are rarely accompanied by symptoms, but can be more marked and persist and require dose reduction or discontinuation (in 3% to 4% of patients). Monthly monitoring of serum aminotransferase levels is recommended, with discontinuation for levels above 8 times the ULN or for values above 5 times the ULN that persist. There have also been rare reports of clinically apparent liver injury with jaundice associated with bosentan use. The onset of illness was usually within 1 to 6 months of starting bosentan, but cases arising during chronic therapy have also been described (Case 1). The enzyme pattern has typically been hepatocellular or mixed. Immunoallergic features are usually not present and autoantibodies are usually absent or present in low titer. Some cases have been severe and fatalities have been reported, but there have been no published reports of chronic hepatitis or vanishing bile duct syndrome attributed to bosentan. Autoimmune and immunoallergic features are usually not present.

Adverse EffectsSafety Profile

화학 및 산업

약리 정보

ATC Code · 3건

C02KX01

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingGreater than 98% to plasma proteins, mainly albumin.
Pharmacodynamics · 1건

Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.

Mechanism of Action · 1건

Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET<sub>A</sub> and ET<sub>B</sub> receptors in the endothelium and vascular smooth muscle. It displays a slightly higher affinity towards ET<sub>A</sub> receptors than ET<sub>B</sub> receptors. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ET<sub>A</sub> and ET<sub>B</sub>.

Biological Half-LifeTerminal elimination half-life is about 5 hours in healthy adult subjects.
Metabolism/Metabolites · 2건

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.

Bosentan has known human metabolites that include 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2-]bipyrimidinyl-4-yl]-benzenesulfonamide and Hydroxy Bosentan.

FDA Pharmacological Classification · 6건

XUL93R30K2

BOSENTAN ANHYDROUS

Established Pharmacologic Class [EPC] - Endothelin Receptor Antagonist

관련 반응

16건
반응 기록 만들기
HRID 97752 반응식
HRID 97752생성물로
HRID 397262 반응식
HRID 397262반응물로
HRID 448549 반응식
HRID 448549생성물로
HRID 448550 반응식
HRID 448550생성물로
HRID 448551 반응식
HRID 448551생성물로
HRID 954007 반응식
HRID 954007생성물로
HRID 1020775 반응식
HRID 1020775생성물로
HRID 1020776 반응식
HRID 1020776생성물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
CAS
147536-97-8
PubChem CID
104865
DTXSID
DTXSID7046627
ChEMBL
CHEMBL957
ChEBI
CHEBI:51450
UNII
XUL93R30K2
EC Number
643-099-1
Nikkaji
J594.472D
밀도
1.325 · 1.325±0.06 g/cm3(Predicted)
저장 조건
-20 °C · -20°C Freezer
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
산도 계수 (pKa)
4.01 · 4.01±0.10(Predicted)
색상
흰색에서 연한 노란색까지

화학적 성질

Pale Yellow to Off-White Solid

Toxicity Summary · 1건

The most frequently observed adverse effect of bosentan overdose is headache. In a cyclosporine A interaction study, administration of 500 mg and 1,000 mg of bosentan twice daily in combination with cyclosporine A resulted in a 30-fold increase in trough plasma concentrations, leading to severe headache, nausea, and vomiting. No serious adverse events were reported. Additional findings included hypotension and tachycardia.

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bosentan

vMost-DILI-concern

7

Box warning

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

HS 번호
29350090

Mechanisms of Action [MoA] - Endothelin Receptor Antagonists

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

Mechanisms of Action [MoA] - Cytochrome P450 2C9 Inducers

MeSH Pharmacological Classification · 2건

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS.

Absorption, Distribution and Excretion · 4건

Absolute bioavailability is approximately 50% and food does not affect absorption.

Bosentan is eliminated by biliary excretion following metabolism in the liver.

18 L

4 L/h [patients with pulmonary arterial hypertension]

Cellular LocationsMembrane

용도 및 제조

UsesUse (kg; approx.) in Germany (2009): >100
응용 분야 · 2건

용도A mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.

일반 설명Bosentan, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tertbutyl-benzenesulfonamide (Tracleer, Bozentan), was thefirst endothelin receptor antagonist marketed in the UnitedStates. Bosentan works by competitively blocking the endothelinreceptor subtypes ETA and ETB. In binding to thereceptors, it blocks the effects of endothelin, which includeconstriction of the vascular smooth muscle, which leads tonarrowing of the blood vessels and hypertension. Althoughit is not selective for the ETA receptors, it does have a higheraffinity for that subtype over ETB. However, the clinical significanceof selectivity over preferential receptor bindinghas not been demonstrated. Bosentan is an inducer ofCYP2C9 and CYP3A4, and patients using bosentan must bemonitored for liver toxicity.

상·하류 제품 정보

상류 원료

주석산 염모노에틸렌글리콜beta-(4-Chlorophenyl)glutaric anhydride나트륨2-아미디노피리미딘염산염4,6-디클로로-5-(2-메톡시페녹시)-2,2'-비피리미딘비천연형 D(-)주석산4-(2-메톡시페닐)헵탄-3,5-디온